Cardio3: Showing heart

Cardio3 hopes for IPO to take autologous stem cell therapy to market for CHF

Treatments for heart failure and myocardial infarction generally address only the symptoms of the disease. Cardio3 BioSciences S.A. believes its stem cell-derived cardiopoietic cells can help repair damaged heart tissue, and says its challenge will be to get to market in order to show potential partners that the business model can make money.

Under a license from the Mayo Clinic, Cardio3 uses a cocktail of undisclosed cardiogenic factors to induce pluripotent stem cells to differentiate into cardiac progenitor cells.

The company's lead therapeutic is C-Cure, an autologous cell therapy for congestive

Read the full 896 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE